1158233-60-3

Usage

Uses

Used in Pharmaceutical Industry:
Methyl [1-(2-chlorophenyl)-5-hydroxy-1H-pyrazol-3-yl]acetate is used as an intermediate in the synthesis of various pharmaceuticals for its potential pharmacological properties. It contributes to the development of drugs that can address specific medical needs, enhancing treatment options for patients.
Used in Agrochemical Industry:
In the agrochemical sector, methyl [1-(2-chlorophenyl)-5-hydroxy-1H-pyrazol-3-yl]acetate is utilized as a precursor in the production of pesticides. Its pesticidal properties make it a valuable component in creating effective solutions to protect crops and ensure agricultural productivity.
It is crucial to handle methyl [1-(2-chlorophenyl)-5-hydroxy-1H-pyrazol-3-yl]acetate with care due to its potential harmful effects if not used properly. The exact applications and properties of methyl [1-(2-chlorophenyl)-5-hydroxy-1H-pyrazol-3-yl]acetate may vary depending on the specific industrial requirements.

Upstream product

• 1830-54-2 3-oxopentanedioic acid dimethyl ester 
• 10449-07-7 (2-chlorophenyl)hydrazine 

Downstream Products

• 1217799-18-2 methyl [(4E)-1-(2-chlorophenyl)-4-(1-ethoxyethylidene)-5-oxo-4,5-dihydro-1H-pyrazol-3-yl]acetate 
• 1350522-88-1 methyl [4-(chloroacetyl)-1-(2-chlorophenyl)-5-hydroxy-1H-pyrazol-3-yl]acetate 
• 1278416-72-0 methyl [(4Z)-4-(4-benzyl-1,4-diazepan-2-ylidene)-1-(2-chlorophenyl)-5-oxo-4,5-dihydro-1H-pyrazol-3-yl]acetate 
• 1278416-40-2 10-benzyl-2-(2-chlorophenyl)-2,3,8, 9,10,11-hexahydro-1H-pyrazolo[4',3':3,4]pyrido[1,2-a][1,4]diazepine-1,5(7H)-dione 
• 1217365-58-6 methyl [4-(chloroacetyl)-1-(2-chlorophenyl)-5-hydroxy-1H-pyrazol-3-yl] acetate 

Relevant academic research and scientific papers

PYRAZOLINE DIONE DERIVATIVES AS NADPH OXIDASE INHIBITORS

The present invention is related to pyrazoline dione derivatives of Formula (I), pharmaceutical composition thereof and to their use for the treatment and/or prophylaxis of disorders or conditions related to Nicotinamide adenine dinucleotide phosphate oxidase (NADPH Oxidase).

Pyrazoline dione derivatives as nadph oxidase inhibitors

The present invention is related to pyrazoline dione derivatives of Formula (I), pharmaceutical composition thereof and to their use for the treatment and/or prophylaxis of disorders or conditions related to Nicotinamide adenine dinucleotide phosphate oxidase (NADPH Oxidase).

Pyrazolo pyridine derivatives as NADPH oxidase inhibitors

The present invention is related to pyrazolo pyridine derivatives of Formula (I), pharmaceutical composition thereof and to their use for the treatment and/or prophylaxis of disorders or conditions related to Nicotinamide adenine dinucleotide phosphate oxidase (NADPH Oxidase).

Pyrazolo pyridine derivatives as NADPH oxidase inhibitors

The present invention is related to pyrazolo pyridine derivatives of Formula (I), pharmaceutical composition thereof and to their use for the treatment and/or prophylaxis of disorders or conditions related to Nicotinamide adenine dinucleotide phosphate oxidase (NADPH Oxidase).

Pyrazolo pyridine derivatives as NADPH oxidase inhibitors

The present invention is related to pyrazolo pyridine derivatives of Formula (I), pharmaceutical composition thereof and to their use for the treatment and/or prophylaxis of disorders or conditions related to Nicotinamide adenine dinucleotide phosphate oxidase (NADPH Oxidase).

First in class, potent, and orally bioavailable NADPH oxidase isoform 4 (Nox4) inhibitors for the treatment of idiopathic pulmonary fibrosis

We describe the design, synthesis, and optimization of first-in-class series of inhibitors of NADPH oxidase isoform 4 (Nox4), an enzyme implicated in several pathologies, in particular idiopathic pulmonary fibrosis, a life-threatening and orphan disease. Initially, several moderately potent pyrazolopyridine dione derivatives were found during a high-throughput screening campaign. SAR investigation around the pyrazolopyridine dione core led to the discovery of several double-digit nanomolar inhibitors in cell free assays of reactive oxygen species (ROS) production, showing high potency on Nox4 and Nox1. The compounds have little affinity for Nox2 isoform and are selective for Nox4/1 isoforms. The specificity of these compounds was confirmed in an extensive in vitro pharmacological profile, as well as in a counterscreening assay for potential ROS scavenging. Concomitant benefits are good oral bioavailability and high plasma concentrations in vivo, allowing further clinical trials for the potential treatment of fibrotic diseases, cancers, and cardiovascular and metabolic diseases.